NYC-based clinics brand Nushama has partnered with Awakn Life Sciences (OTCQB:AWKNF), a clinical-stage psychedelics biotech company to bring Awakn’s advanced ketamine-assisted therapy treatment for AUD to Nushama’s New York clinics. They intend to provide sustained relief from depression, anxiety, chronic pain, addiction and trauma-induced mood disorders with high-dose IV Ketamine.
This is the first time the KARE (Ketamine for Reduction of Alcoholic Relapse) protocol is being offered in New York City medical facilities. Nushama's co-founder and president Richard Meloff is optimistic about the new collaboration’s ability to deliver positive outcomes for patients in need of treatment: 2022 numbers show 63.3% of excessive alcohol use deaths are from chronic causes -such as Alcohol Use Disorder.
